Argenica Therapeutics Ltd (AU:AGN) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argenica Therapeutics Ltd has received a positive safety review from the independent Data Safety Monitoring Board for its Phase 2 trial of ARG-007 in stroke patients, with no serious adverse events reported. The trial is progressing well, with 63% of patient dosing completed across activated hospital sites. The company anticipates full dosing completion by mid-2025, with topline data expected shortly after.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.